City University of New York (CUNY)

CUNY Academic Works
Publications and Research

Hunter College

2012

Coordination between proteasome impairment and caspase
activation leading to TAU pathology: neuroprotection by cAMP
M. J. Metcalfe
CUNY Hunter College

Q. Huang
CUNY Hunter College

Maria E. Figueiredo-Pereira
CUNY Hunter College

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/hc_pubs/297
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Citation: Cell Death and Disease (2012) 3, e326; doi:10.1038/cddis.2012.70
& 2012 Macmillan Publishers Limited All rights reserved 2041-4889/12

www.nature.com/cddis

Coordination between proteasome impairment and
caspase activation leading to TAU pathology:
neuroprotection by cAMP
MJ Metcalfe1, Q Huang1 and ME Figueiredo-Pereira*,1

Neurofibrillary tangles (NFTs) are hallmarks of Alzheimer’s disease (AD). The main component of NFTs is TAU, a highly soluble
microtubule-associated protein. However, when TAU is cleaved at Asp421 by caspases it becomes prone to aggregation leading
to NFTs. What triggers caspase activation resulting in TAU cleavage remains unclear. We investigated in rat cortical neurons
a potential coordination between proteasome impairment and caspase activation. We demonstrate that upon proteasome
inhibition, the early accumulation of detergent-soluble ubiquitinated (SUb) proteins paves the way to caspase activation and TAU
pathology. This occurs with two drugs that inhibit the proteasome by different means: the product of inflammation prostaglandin
J2 (PGJ2) and epoxomicin. Our results pinpoint a critical early event, that is, the buildup of SUb proteins that contributes to
caspase activation, TAU cleavage, TAU/Ub-protein aggregation and neuronal death. Furthermore, to our knowledge, we are the
first to demonstrate that elevating cAMP in neurons with dibutyryl-cAMP (db-cAMP) or the lipophilic peptide PACAP27 prevents/
diminishes caspase activation, TAU cleavage and neuronal death induced by PGJ2, as long as these PGJ2-induced changes
are moderate. db-cAMP also stimulated proteasomes, and mitigated proteasome inhibition induced by PGJ2. We propose
that targeting cAMP/PKA to boost proteasome activity in a sustainable manner could offer an effective approach to avoid
early accumulation of SUb proteins and later caspase activation, and TAU cleavage, possibly preventing/delaying AD
neurodegeneration.
Cell Death and Disease (2012) 3, e326; doi:10.1038/cddis.2012.70; published online 21 June 2012
Subject Category: Neuroscience

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder. Little is known about the initial pathology, and
when symptoms are detected, neurodegeneration is so
advanced that it is seldom reversible. Neurofibrillary tangles
(NFTs) are pathological hallmarks of AD. The major component of NFTs is TAU, a microtubule-associated protein that is
abundant in neurons and highly soluble; yet TAU aggregates
abnormally in AD.1 Truncation of TAU at Asp421 (DTAU) by
caspases is an early event in AD tangle pathology.2–4 In
addition, DTAU is detected in NFTs, indicating that the
apoptotic cascade is involved in NFT formation.5
The initial events leading to caspase activation and DTAU
are poorly defined. We propose that proteasome impairment
could be one of the initial critical events that contributes and
leads to caspase activation concurring with DTAU, protein
aggregation and neuronal death. There is a general agreement that proteasome impairment is involved in the pathogenesis of AD. Defective proteasome activity is connected to
the early phase of AD characterized by synaptic dysfunction,
as well as to late AD stages linked to accumulation and

aggregation of ubiquitinated (Ub) proteins in both senile
plaques and NFTs.6,7
To investigate a potential coordination between proteasome impairment and caspase activation leading to TAU
pathology, we treated rat cerebral cortical neurons with two
drugs that inhibit the proteasome by different means:
prostaglandin J2 (PGJ2) and epoxomicin. PGJ2 is an
endogenous product of inflammation that inhibits the proteasome by inducing oxidation of its subunit S6 ATPase (Rpt5),8
and/or by promoting dissociation of the 26S proteasomes.9
By promoting 26S proteasome disassembly, PGJ2 resembles
the effects of agents that induce oxidative stress.10 We
recently demonstrated in rat cortical neurons that PGJ2
induces accumulation of Ub proteins, caspase activation,
DTAU and its aggregation, as well as neuritic dystrophy.11
Epoxomicin is a specific and irreversible inhibitor of the
proteasome that forms a covalent adduct with the amino
terminal Thr of the 20S proteasome catalytic subunits,
generating irreversible morpholino adducts.12 Other proteasome inhibitors, that is, MG132 and lactacystin, were shown
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to induce apoptosis via caspase activation in rat cortical
neurons, but Ub protein accumulation/aggregation and TAU
pathology were not addressed.13
We report now that in rat cortical neurons, the buildup of
detergent (NP40) -soluble Ub (SUb) proteins induced by
PGJ2 or epoxomicin was detected significantly earlier than
caspase activation, DTAU and TAU/Ub-protein aggregation.
In addition, to our knowledge, we are the first to report that
elevating cAMP via treatment with a single dose of dibutyrylcAMP (db-cAMP) or the lipophilic peptide PACAP27 prevents
caspase activation, DTAU and protein aggregation induced by
short-term incubations (up to 8 h) with PGJ2. In the cortical
neurons, db-cAMP alone also increased 26S proteasome
activity significantly, and reduced 26S proteasome inhibition
by PGJ2. Furthermore, db-cAMP and PACAP27 offered
neuroprotection against short-term incubations with PGJ2.
In long-term studies (24 h), three consecutive doses of the
cAMP-elevating drugs administered 4 h apart, reduced
changes induced by PGJ2. Altogether, these data support
the notion that targeting the cAMP/PKA (cAMP-dependent
protein kinase) pathway to stimulate 26S proteasome activity
in a robust and sustainable manner could prevent the early
accumulation of SUb proteins, and later avoid caspase
activation leading to TAU cleavage and TAU pathology. If
applied early before neurons reach a point of no return,
elevating cAMP could be an effective therapeutic strategy to
prevent/delay neurodegeneration associated with protein
aggregation in AD.
Results
Detergent (NP40) -SUb proteins accumulate early upon
proteasome inhibition, and before caspase activation,
as well as DTAU formation. We investigated a temporal
correlation between proteasome inhibition and caspase
activation by treating rat cortical neurons with PGJ2
(Figure 1a) or epoxomicin (Figure 1b). The time-course
studies clearly demonstrate that detergent (NP40) -SUb
proteins are detected upon a 4 h treatment with 20 mM PGJ2
or 20 nM epoxomicin (Figures 1a and b, panel 1), the earliest
time point analyzed. Robust aggregates of Ub proteins, as
well as caspase 3 activation, DTAU formation and TAU
aggregates (Figures 1a and b, panels 2 to 6, respectively)
were detected much later, that is, after at least 16 h of

treatment. Large (40.2 mm), sodium dodecyl sulfate (SDS)insoluble Ub- and TAU aggregates were assessed with the
filter trap assay. Remarkably, the decline in SUb proteins
observed at 16 and 24 h corresponds to a robust increase in
Ub aggregates. SUb proteins are considered here to be
those that are NP40-soluble, and Ub aggregates those that
are NP40-insoluble as well as those that are retained with the
filter trap assay.
It is important to clarify that the TAU C3 antibody, which
specifically detects TAU cleaved at Asp421 (DTAU, epitope
(Ep) a.a. 412–421), reacts with two bands. The upper band is
often detected under control conditions, that is, in cells treated
with dimethyl sulfoxide (DMSO; vehicle) alone. The lower
band concurs with TAU aggregates and appears only under
conditions of robust caspase activation (see Figures 1a and b,
panels 4 and 5). We thus consider the lower band to be
the major product of caspase cleavage of TAU at Asp421.
Probing the western blots with the TAU C5 antibody (Ep
a.a. 210–241, Figures 1a and b, panel 7) detected the entire
full-length TAU isoforms (Tau FL) as well as DTAU, the latter
with a pattern similar to the one obtained with the TAU C3
antibody.
Notably, proteasome inhibition for 48 h with epoxomicin did
not increase the level of full-length TAU nor did it generate
high-molecular-weight forms of TAU corresponding to UbTAU (Figure 1b, panel 7). Instead, epoxomicin caused an
accumulation of various TAU fragments ranging in size
between 37 kDa and 15 kDa, thus smaller than DTAU. These
data indicate that upon TAU cleavage at Asp421 by caspases,
TAU is further cleaved by unidentified proteases that generate
smaller fragments detected upon proteasome inhibition. Actin
levels (Figures 1a and b, panel 8) were not altered by the
treatments.
We assessed with the native in gel assay, the effects of
PGJ2 and epoxomicin on proteasome activity and levels in the
cortical neurons. This assay detects the three native proteasome forms: 26S with two regulatory caps [26S(2)] or one cap
[26S(1)], and the 20S core particle alone (20S). Proteasome
chymotrypsin-like activity was determined with the substrate
succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (SucLLVY-AMC; Figures 1a and b, panel 10). Under control
conditions (first lanes), the activity of the 20S proteasome
is substantially lower than the 26S, because the 20S is a
latent form of the proteasome.14 Proteasome levels were

Figure 1 Accumulation of NP40-SUb proteins paves the way for caspase 3 activation, caspase-mediated TAU cleavage (DTAU) and aggregation of Ub proteins as well
as TAU, induced by PGJ2 (a) or epoxomicin (b). Western blot analyses to detect Ub proteins (NP40-soluble and NP40-insoluble), caspase 3, TAU cleaved at Asp421 (DTau),
full-length TAU (Tau FL) and actin (loading control) in cell extracts of rat E18 cerebral cortical neurons (40 mg of protein/lane). The cortical neurons were treated with 20 mM
PGJ2 (a) or 20 nM epoxomicin (b) for different time points. Cell extracts were subjected to centrifugation to separate the NP40-soluble and NP40-insoluble fractions as
described under ‘Materials and Methods’. The blots were probed with anti-Ub proteins antibody (panels 1, 2 and 3), caspase 3 (panel 4), TAU C3 antibody (TAU cleaved at
Asp421, epitope a.a. 412-421, panels 5 and 6), TAU C5 antibody (detects all TAU isoforms and DTAU; ep: a.a. 210–241, panel 7) and anti-actin antibody (panel 8). Molecular
mass markers in kDa are shown in the middle. Ub aggregates (Ub-agg.) and DTAU aggregates (DTau-agg.) were analyzed with the filter trap assay (50 mg of protein/dot,
panels 3 and 6). The levels of NP40-soluble Ub proteins (solid squares), cleaved caspase 3 (crosses) and DTAU (open squares) were semi-quantified by densitometry
(panel 9). Data represent the percentage of the pixel ratio for soluble Ub proteins, cleaved caspase 3 or DTAU, over actin for each condition compared with control (100%).
Values are means±S.D. from at least two experiments. Asterisks identify values that are significantly different from control (**Po0.01, ***Po0.001). Ub proteins, Ub
proteins; DTau, TAU cleaved at Asp421; Tau FL, full-length TAU. To assess changes in proteasome activity, cell extracts were prepared from rat E18 cerebral cortical
neurons treated with 20 mM PGJ2 (a) or 5 nM epoxomicin (b) for different time points. Clear lysates (30 mg/sample) were subjected to non-denaturing gel electrophoresis as
described under ‘Materials and Methods’. 26S and 20S proteasomal (indicated in the middle by arrows) chymotrypsin-like activity was assessed with Suc-LLVY-AMC by the
in gel assay (panel 10). Proteasome levels were detected by immunoblotting with the anti-b5 antibody (panel 11). The numbers at the bottom of panels 10 and 11 represent
26S and 20S proteasomal chymotrypsin-like activity and levels, respectively, under each treatment condition. Percentages represent the ratio between data for each
condition and control (DMSO) considered to be 100%. Values are means from duplicate experiments
Cell Death and Disease
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established by immunoblotting with an anti-b5 antibody
(Figures 1a and b, panel 11). The b5 subunit is a component
of the 20S core, thus the antibody detects both 26S and the
20S proteasomes. PGJ2 and epoxomicin inhibited the 26S
proteasome in a manner that parallels the accumulation of Ub
proteins induced by both drugs. Furthermore, PGJ2 caused
26S proteasome disassembly, whereas 20S proteasome
levels increased (Figure 1a, panel 11). We used lower
epoxomicin concentrations in this assay to be able to
determine the gradual time-dependent decrease in proteasome activity, which by 16 h was low (Figure 1b, panel 10).
db-cAMP and PACAP27 prevent the decrease in cAMP
induced by PGJ2. PGJ2 is derived from prostaglandin D2
(PGD2), the major product of cyclooxygenases in the
mammalian central nervous system.15 PGJ2 signals via
one of the PGD2 receptors, that is, the DP2 receptor, which
is coupled to inhibitory G proteins thus lowering cAMP.16,17
As cAMP has neuroprotective effects,18 to overcome the
decline in cAMP induced by PGJ2, we tested two drugs: (1)
db-cAMP, which is more cell permeable and resistant to
cyclic phosphodiesterases than cAMP19 and (2) PACAP27
(pituitary adenylate cyclase-activating polypeptide), which is
a lipophilic peptide that binds to the seven transmembrane
G-coupled receptor PAC1R (pituitary adenylate cyclase 1
receptor) at nanomolar levels, activating adenylate cyclase
and elevating cAMP.20 PAC1R is expressed in the cerebral
cortex, hippocampus and other brain areas.21 In our studies,
db-cAMP was added to the cultures 30 min before PGJ2,
whereas PACAP27 was added in conjunction with PGJ2.
Compared with control conditions, PGJ2 (10 mM, 4 h)
decreased cAMP levels by almost 3-fold, whereas db-cAMP
(1 mM) and PACAP27 (100 nM) increased cAMP by 4-fold and
2.5-fold, respectively (Figure 2). In the presence of PGJ2, dbcAMP and PACAP27 still raised cAMP levels, by 8.4-fold and 4.8fold, respectively, when compared with PGJ2 alone. Remarkably,
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Figure 2 Dibutyryl-cAMP (db-cAMP) and PACAP27 prevent the decrease in
cAMP induced by PGJ2. Rat E18 cerebral cortical neurons were treated with water
(vehicle, control), db-cAMP (1 mM) or PACAP27 (100 nM) in conjunction with
DMSO (vehicle, control, white bars) or with 10 mM PGJ2 (black bars) for 4 h.
Intracellular cAMP was measured with an EIA kit as described under ‘Materials and
Methods’. Levels of intracellular cAMP in the cortical neurons are expressed as
pmoles per mg of protein. Values represent means and S.E. from three experiments.
Asterisks identify values that are significantly different in a comparison between
PGJ2 alone and PGJ2 with db-cAMP (***Po0.001) or between PGJ2 alone and
PGJ2 with PACAP27 (*Po0.05)
Cell Death and Disease

PACAP27 elevated intracellular cAMP at drastically lower
(nanomolar) concentrations than db-cAMP (millimolar).
Db-cAMP and PACAP27 prevent activation of caspases
8 and 3 induced by PGJ2. PGJ2 treatment promotes
activation of the initiator caspase 8 (extrinsic pathway) in a
time-dependent manner (Figure 3a) similar to activation of
the effector caspase 3 (Figure 1a, panel 4). Caspase
activation was assessed by western blotting that detects
conversion of pro-caspase 8 and 3 into their cleaved active
forms, and with a colorimetric assay (Figure 3). Caspases 3
(Figure 3c) and 8 (Figure 3d) were significantly (Btwofold,
Po0.001) activated by PGJ2 treatment (8 h, 10 mM).
Db-cAMP and PACAP27 stopped/reduced caspase activation triggered by PGJ2 (Figures 3c and d). Caspase 9 was
not affected by PGJ2 (Figures 3b and e).
Db-cAMP and PACAP27 prevent DTAU formation
induced by PGJ2. The formation of DTAU triggered by
short-term (up to 8 h) incubations with PGJ2 was blocked/
reduced by db-cAMP (1 mM) and PACAP27 (100 nM; rows 1,
Figures 4a and b), respectively. A similar trend was observed
for activation of caspase 8 and 3. Both cAMP-elevating drugs
prevented/diminished the conversion of procaspase 8 and 3
to the respective cleaved forms upon short-term (up to 8 h)
treatment with PGJ2 (10 mM, rows 2 and 3, Figures 4a
and b).
Upon long-term (16 and 24 h) incubations with PGJ2, the
protective effect of a single dose of db-cAMP or PACAP27
related to DTAU and caspase activation was dissipated.
PACAP27 was less efficient than db-cAMP at all times. The
lanes from each gel were separated into consecutive pairs to
facilitate comparing the effect of PGJ2 alone (  ) with the
combination of PGJ2 plus db-cAMP or PACAP27 ( þ ).
These data demonstrate that elevating intracellular cAMP
prevents caspase-dependent DTAU formation triggered by
short-term incubations (up to 8 h) with PGJ2. The protective
effect of one single dose of db-cAMP or PACAP27 against
longer PGJ2 treatments (16 and 24 h) faded away.
Db-cAMP stimulates proteasomal activity in a PKAdependent manner and reduces 26S proteasome
inhibition by PGJ2. One single dose of db-cAMP (1 mM)
increased the activity and levels of both forms of the 26S
proteasome in the cortical neurons (Figures 5a and b,
panel 1, lane d). The activity of the 20S particle was also
elevated without major changes in its levels. cAMP is known to
exert its action by targeting PKA and/or Epac (exchange
protein directly activated by cAMP) (reviewed in Cheng
et al.22). We show that stimulation of the proteasome by dbcAMP was PKA dependent, as it was abolished by pretreatment with adenosine 3’,5’-cyclic monophosphorothioate (RpcAMPS; Figures 5a and b, panel 1, lanes d and e). Rp-cAMPS
is a PKA inhibitor that acts as a competitive antagonist of the
cyclic-nucleotide-binding domains on PKA.23
Db-cAMP reduced the inhibitory effect of PGJ2 on the
26S proteasome, albeit proteasome activity and levels were
not completely preserved (Figures 5a and b, panel 2, compare
lanes b and d). In addition, db-cAMP alone increases
proteasome activity via PKA.
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Although PACAP27 elevates cAMP, we did not observe
any effect of the peptide on 26S proteasomes upon 24 h
treatment (Figures 5a and b, all panels, lanes f and g). This is
most likely due to rapid hydrolysis of cAMP generated by
treatment with the peptide (see Discussion).
Db-cAMP and PACAP27 prevent the formation of Ub
protein aggregates induced by PGJ2. Both cAMP-elevating drugs prevented Ub-protein aggregation induced by 8 h
treatment with PGJ2 (Figure 6a, upper panel). However, this
effect was dissipated upon longer (24 h) PGJ2 incubations

(Figure 6a, lower panel). Db-cAMP reduced 26S proteasome
inhibition induced by 8 h as well as 24 h treatments with
PGJ2, but proteasome activity was never recovered to 100%
(Figure 6b). Thus, the beneficial effect of one single dose of
db-cAMP on the proteasome effectively prevented protein
aggregation upon short-term but not long-term treatment with
PGJ2. For simplicity, only the activity of the 26S proteasome
with one cap [26S(1)] was quantified, as it is the strongest of
the three proteasome forms detected.
The levels of NP40-SUb proteins induced by PGJ2 were not
altered by db-cAMP (Figures 6c and d) or PACAP27 (not shown).
Cell Death and Disease
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Figure 4 Db-cAMP (1 mM, a) and PACAP27 (100 nM, b) prevent/reduce caspase-mediated cleavage of TAU at Asp421 (DTAU) induced by short-term (up to 8 h) but not
long-term (at least 16 h) incubations with PGJ2. Western blot analyses to detect TAU cleaved at Asp421 (DTAU, rows 1), caspase 8 (rows 2), caspase 3 (rows 3) and actin
(rows 4, loading control) in extracts of rat E18 cerebral cortical neurons (40 mg of protein/lane). The cortical neurons were treated with water (minus sign, vehicle, control),
db-cAMP ((a) plus sign, 1 mM) or PACAP27 ((b) plus sign, 100 nM) in conjunction with DMSO (vehicle, control) or 10 mM PGJ2 for different time points (4, 8, 16 and 24 h). The
blots were probed with the respective antibodies. Molecular mass markers in kDa are shown on the right. Similar results were obtained in duplicate experiments. DTau, TAU
cleaved at Asp421; Pro, zymogenic; and Cl, cleaved forms of the caspases

We conclude that improvement of proteasome activity by
one single dose of db-cAMP was not enough to completely
overcome accumulation/aggregation of Ub proteins. Although
db-cAMP reduced Ub aggregates formed upon 8 h treatment
with PGJ2, in longer treatments the effect of PGJ2 prevailed
over the cAMP analog.
Db-cAMP and PACAP27 prevent the loss of cell viability
induced by PGJ2. PGJ2 treatment is neurotoxic in a timeand concentration-dependent manner (Figure 7a). Db-cAMP
(1 mM, Figures 7b and c) and PACAP27 (25–100 nM,
Cell Death and Disease

Figure 7d) significantly (Po0.001) reduced the loss of
viability induced by short-term (8 h) treatment with PGJ2.
However, neuroprotection by a single dose of db-cAMP, the
more effective of the two cAMP-elevating drugs, was lost
against longer (24 h) incubations with PGJ2.
Three doses of db-cAMP or PACAP27 reduce the
changes induced by long-term (24 h) incubations with
PGJ2. As shown in Figure 7, the viability of the cells upon
long-term (24 h) incubations with PGJ2 decreases to about
50%. To overcome the long-term effects of PGJ2, we
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Figure 5 Db-cAMP stimulates 26S proteasomes via PKA, and reduces 26S proteasome inhibition by PGJ2; no changes in 26S proteasome activity were detected with
PACAP27. Extracts were prepared from rat E18 cerebral cortical neurons treated with water (control, vehicle), db-cAMP (1 mM, db-cAMP) without or with Rp-cAMPS (100 mM,
1 h pretreatment, Rp), PACAP27 (100 nM) without or with Rp-cAMPS, in conjunction with DMSO (24 h, control, vehicle, panel 1) or with PGJ2 (24 h, 10 mM, panel 2).
Rp-cAMPS is a PKA inhibitor. Cleared cell lysates (30 mg/sample) were subjected to non-denaturing gel electrophoresis as described under ‘Materials and Methods’. 26S and
20S proteasomal chymotrypsin-like activities (indicated on the left by arrows) were assessed with Suc-LLVY-AMC by the in-gel assay (a panels 1 and 2). Proteasome levels
were detected by immunoblotting with anti-b5 (b panels 1 and 2). The numbers at the bottom of each panel represent 26S and 20S proteasomal chymotrypsin-like activity and
proteasome levels under each treatment condition. Percentages represent the ratio between data for each condition and control (DMSO, 100%). Values are from a
representative experiment. Similar results were obtained in duplicate experiments

increased the number of treatments with the cAMP-elevating
drugs as described under ‘Materials and Methods’. As shown
in Figure 8, three doses of db-cAMP (1 mM) or PACAP27
(100 nM) clearly diminished the levels of DTAU (panel 1),
DTAU aggregates (panel 2), caspase 3 cleavage (panel 3),
soluble Ub proteins (panel 4), Ub-protein aggregates (panel
5) and loss of cell viability (panel 7) induced by 24 h treatment
with 5 mM PGJ2. Incubations with 10 mM PGJ2 caused more
severe changes than 5 mM PGJ2, and thus were harder to
overcome. In the absence of PGJ2, three doses of the
cAMP-elevating drugs did not alter the levels of the proteins
tested (not shown). In addition, treatment with just two doses
of the cAMP-elevating drugs was ineffective against PGJ2
(not shown).
Discussion
Our current data with rat cerebral cortical neurons demonstrate a temporal correlation between proteasome inhibition
and caspase activation that leads to TAU cleavage at Asp421

associated with TAU pathology and cell death. The temporal
correlation depicts the accumulation of detergent (NP40)SUb proteins occurring early upon proteasome impairment.
Caspase activation, TAU cleavage at Asp421 and the
aggregation of TAU and Ub proteins occur significantly later.
Large aggregates (detected with the filter trap assay) also
appear late in this toxic cascade. The filter trap assay captures
large (40.2 mm) and SDS-insoluble aggregates.24 The sequence of proteolysis-related events was triggered by the
product of inflammation PGJ2 and the specific proteasome
inhibitor epoxomicin. Although PGJ2 mimics the effect of
some oxidative stressors by causing dissociation of 26S
proteasomes,9,10 epoxomicin forms covalent adducts with
the 20S proteasome active sites.12 The finding that both drugs
induce a similar temporal response to proteasome impairment
suggests that these proteolysis-related events could be
shared by various proteotoxic conditions that induce a decline
in proteasome activity in neurons. This temporal response to
proteasome inhibition strongly supports the notion that the
accumulation of SUb proteins, if not resolved, could be one of
Cell Death and Disease
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Figure 6 Db-cAMP (1 mM) reduces Ub aggregates and 26S proteasome inhibition induced by PGJ2; accumulation of NP40-soluble Ub proteins triggered by PGJ2 was
not affected by db-cAMP. (a) Ub aggregates (50 mg of protein/dot) were analyzed with the filter trap assay as described under ‘Materials and Methods’. (b) 26S and 20S
proteasomal chymotrypsin-like activities were assessed with Suc-LLVY-AMC by the in-gel assay as described under ‘Materials and Methods’. The numbers under the panels
represent in (a) ubiquitin aggregates, and in (b) 26S and 20S proteasomal chymotrypsin-like activity. Percentages represent the ratio between data for each condition and
control (DMSO, 100%). Values are from a representative experiment. Similar results were obtained in duplicate experiments. (c) Western blot analyses to detect NP40-soluble
Ub proteins and actin (loading control) in extracts of rat E18 cerebral cortical neurons (40 mg of protein/lane). The cortical neurons were treated with water (minus sign, vehicle,
control) or db-cAMP ((c) plus sign, 1 mM) in conjunction with DMSO (vehicle, control) or 10 mM PGJ2 for different time points (4, 8, 16 and 24 h). The blots were probed with
the respective antibodies. Molecular mass markers in kDa are shown on the right. The levels of NP40-soluble Ub proteins were semi-quantified by densitometry (d). Data
represent the percentage of the pixel ratio for soluble Ub proteins over actin for each condition compared with control (100%). Values are means and S.E. from three
experiments

the critical events triggering caspase activation that mediates
TAU cleavage and generates aggregation-prone fragments
of TAU. Other studies support this notion. For example, 26S
proteasome dysfunction was sufficient to trigger neurodegenerative disease in a transgenic mouse model developed by
conditionally depleting a 26S proteasome subunit in forebrain
neurons.25 The mutant mice exhibited diffuse accumulation of
Ub proteins in forebrain neurons at 2 weeks of age. Caspase
activation and intraneuronal Ub-positive inclusions were
observed later, at 4 weeks of age, indicating extensive
Cell Death and Disease

neurodegeneration in the targeted neurons.25 In another
study, proteasome impairment was found to occur early in the
progression of the pathological events detected in 3  Tg-AD
mice, leading to Ab and TAU accumulation.26 Based on these
studies, we propose that elevating proteasome activity to
prevent the accumulation of SUb proteins early in the
neurodegenerative process could be an effective approach
to prevent caspase activation and TAU pathology.
Notably, we found that a single dose of db-cAMP increases
26S proteasome activity via PKA activation in the cortical
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neurons. Others established a similar phenomenon in 293
cells 27 and in myocardium.28 The latter studies demonstrated
that PKA stimulation increased the activity of the 26S
proteasome via subunit phosphorylation and/or transcription.
In our experiments with the cortical neurons, proteasome
stimulation promoted by a single dose of db-cAMP mitigated
proteasome inhibition induced by PGJ2. Under the conditions
tested, we did not observe proteasome stimulation by
PACAP27, although the peptide elevates intracellular cAMP.
This is not surprising, as cAMP is significantly more susceptible to hydrolysis by cyclic phosphodiesterases than its
analog db-cAMP. Cyclic phosphodiesterases exhibit very
rapid kinetics for cAMP degradation, compared with cAMP
synthesis by adenylate cyclases.29 It is likely that to maintain
proteasome activity via db-cAMP or PACAP27 on a long-term
basis under proteotoxic conditions, these drugs have to be
delivered more than once, and not as a single dose. PACAP27
may be preferred over db-cAMP, as the latter was shown to
have adverse biological effects when administered in vivo.30
Once prolonged 26S proteasome stimulation is attained, it
could prevent the early accumulation of SUb proteins and
avoid later on caspase activation, protein aggregation and
neurons from reaching a point of no return.
We also demonstrate, for the first time to our knowledge,
that elevating cAMP via db-cAMP or PACAP27 prevents
caspase activation and generation of DTAU induced by PGJ2.
TAU proteolysis is recognized as having an important role
in TAU aggregation and neurodegeneration in AD.2,3 Thus,
blocking TAU cleavage at Asp421 could be a potential
therapeutic approach against TAU pathology. We show that
only a single dose of db-cAMP or PACAP27 blocked caspase
activation and DTAU upon short-term (up to 8 h) treatment
with PGJ2. As shown in Figure 7, the viability of the cells upon
long-term (24 h) incubations with PGJ2 decreases to about
50%. To attempt to overcome the harsh effects of long-term
(24 h) incubations with PGJ2, we decided to increase the
number of treatments with the cAMP-elevating drugs. Administration of three sequential doses of the cAMP-elevating
drugs was necessary to diminish DTAU, caspase activation
and loss of cell viability promoted by long-term (24 h)
incubations with 5 mM PGJ2. It is notable that PACAP27
mimics the protective effects of db-cAMP at considerably
lower concentrations (nanomolar for PACAP27 versus millimolar for db-cAMP). The difference in effectiveness could be
due to some properties of db-cAMP, such as that it remains
inactive until endogenous esterases/amylases remove the
butyrate.31 Furthermore butyrate, by itself, affects gene
transcription and PKC, thus interfering with several cAMPdependent pathways.31 As discussed above in relation to
PACAP27, treatment with a single dose of the peptide
is unlikely to be optimal and/or maximized for long-term
neuroprotection, because its action depends on the production of hydrolysable cAMP. This notion is supported by our
data showing that three consecutive doses of the cAMPelevating drugs diminish long-term (24 h) effects of PGJ2.
Interestingly, PACAP was shown to enhance a-secretase
activity32 and improve memory in rats.33 That PACAP27
shows promise in delaying AD is corroborated by a recent
study showing that long-term daily intranasal administration
of PACAP slowed down AD-like pathology in APP[V717I]
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Figure 7 Db-cAMP (1mM) and PACAP (100 nM) prevent/reduce the loss of cell
viability induced by short-term (8 h) incubations with PGJ2. Rat E18 cerebral cortical
neurons were treated: in (a) with DMSO (0, control), or increasing concentrations
of PGJ2 for 4, 8, 16 or 24 h; in (b) and (c) with water (control, vehicle, minus sign)
or db-cAMP (1 mM, db-cAMP, plus sign) in conjunction with DMSO (vehicle, not
shown) or PGJ2 (b, 10 mM, c, 15 mM) for 8, 16 and 24 h; in (d) with water (control,
vehicle, not shown) or with PACAP27 (25, 50, 100 or 200 nM) in conjunction
with DMSO (vehicle, minus sign) or PGJ2 (10 mM, plus sign) for 8 h. Cell viability
was assessed with the MTT assay as described under ‘Materials and Methods’.
Percentages represent the ratio between the data for each condition and control
(100%). Values indicate means and S.E. from at least three experiments. Asterisks
identify values that are significantly different in (a) from control, in (b) and (c)
between PGJ2 alone and PGJ2 with db-cAMP, and in (d) between PGJ2 alone and
PGJ2 with PACAP27, *Po0.05, **Po0.01, ***Po0.001

AD transgenic mice.34 In the latter studies, TAU pathology was
not addressed. Together these results support the view that,
due to its beneficial properties, PACAP27 could be a very
Cell Death and Disease
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Figure 8 Three doses of db-cAMP (1 mM) or PACAP (100 nM) diminish the
effects of long-term (24 h) incubations with PGJ2. Rat E18 cerebral cortical neurons were
treated with DMSO (0, control, vehicle for PGJ2) or PGJ2 (5 or 10 mM) in conjunction with
three consecutive doses of water (control, vehicle for db-cAMP and PACAP27), db-cAMP
(1 mM, db-cAMP) or PACAP27 (100 nM) over a period of 24 h. The cAMP-elevating drugs
were added as described under ‘Materials and Methods’. Western blots of the NP-40
soluble fractions (30 mg of protein/lane) were probed for TAU cleaved at Asp421 (DTAU,
panel 1), caspase 3 (panel 3), soluble Ub proteins (panel 4) and actin (panel 6, loading
control). DTAU- and Ub aggregates (panels 2 and 5) were assessed with the filter trap
assay (30 mg of protein/dot). Molecular mass markers in kDa are shown on the right.
Similar results were obtained in duplicate experiments. DTau, TAU cleaved at Asp421;
Pro, zymogenic; and Cl, cleaved forms of caspase 3. Cell viability (panel 7) was assessed
with the MTT assay. Percentages represent the ratio between the data for each condition
and control (100%). Values indicate means and S.E. from six determinations. Asterisks
identify values that are significantly different from treatment with water alone or db-cAMP
alone (white bars, respectively) within each group, with ***Po0.001. Dashed lines
compare conditions that are not significantly different

interesting agent for long-term treatment of AD (reviewed in
Reglodi et al.35). The challenge is to identify which mechanisms PACAP27 is triggering to bring about its protective
effects.
Cell Death and Disease

In conclusion, our data clearly demonstrate that the
accumulation of SUb proteins is an early event that occurs
after treating cortical neurons with two drugs, that is, PGJ2
and epoxomicin, that inhibit the proteasome by different
means. As there is compelling evidence for impairment of
proteasome activity in AD 36 and aging,37 it is possible that the
sequence of proteolysis-related events that we established
here and that are triggered by PGJ2 and epoxomicin is similar
in the early stages of neurodegeneration in AD (modeled in
Figure 9). Initially, low levels of SUb proteins that escape
degradation accumulate in the affected areas of the AD brain.
These SUb proteins could further exacerbate proteasome
malfunction. Several studies demonstrate that increasing the
levels of polyubiquitin chains38 and/or aggregation prone
proteins, such as PHF-TAU,39 decreases proteasome activity. When these proteins accumulate in the cell, they can bind
to proteasomes and block access of other substrates to the
proteasomal-degradation machinery, thus further aggravating the proteotoxic situation. With time, proteasome activity
continues to deteriorate to a point that the neurons can no
longer cope with the proteotoxic stress and reach a point of no
return. This feed-forward incremental proteasome inhibition
could be a major factor in neurodegeneration. We propose
(modeled in Figure 9) that targeting the proteasome to
enhance its activity in a robust and sustainable manner via
cAMP/PKA signaling could avoid the early accumulation of
SUb proteins, followed later on, by caspase activation and
protein aggregation. An early intervention strategy could
prevent neurons from reaching a point of no return, and
provide an effective therapy to avoid/delay neurodegeneration in AD.
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Materials and Methods
Materials. PGJ2 was from Cayman Chemical (Ann Arbor, MI, USA) and
epoxomicin from Peptides International Inc. (Louisville, KY, USA). Adenosine 30 ,
50 -cyclic monophosphate dibutyryl sodium salt (db-cAMP), Rp-cAMPS, triethylammonium salt (Rp-isomer) and the cAMP colorimetric direct immunoassay Kit
were from Calbiochem/EMD Bioscience (Gibbstown, NJ, USA). The 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) was from SigmaAldrich (St. Louis, MO, USA). The substrate Suc-LLVY-AMC and the peptide
PACAP27 were from BACHEM Bioscience Inc. (King of Prussia, PA, USA).
Antibodies: rabbit polyclonal anti-Ub-proteins (1:1,500, cat# Z0458, Dako, North
America, Carpinteria, CA, USA); rabbit polyclonal anti-b5 (1:1,000, cat# PW8895)
from BIOMOL (Plymouth Meeting, PA, USA); mouse monoclonal anti-b-actin
(1:10,000, cat# A2228, Sigma, St. Louis, MO, USA); rabbit polyclonal anti-caspase
8 (1:500, cat# 3020) and anti-caspase 9 (1:1,000, cat# 3016) from BioVision
(Mountain View, CA, USA); mouse monoclonal TAU C3 (1:5,000; detects TAU
cleaved at Asp421; Ep: a.a. 412–421) and mouse monoclonal TAU C5 (1:50,000;
detects all TAU isoforms and DTAU; Ep: a.a. 210–241) were courtesy of
Dr. L Binder (Northwestern University, Chicago, IL, USA); rabbit polyclonal anticaspase 3 (1:1000, cat# 9662, Cell Signaling Technology, Danvers, MA, USA).
The respective secondary antibodies with HRP conjugate (1:10,000) were from
BioRad Laboratories (Hercules, CA, USA).
Cell cultures. Dissociated cultures from Sprague Dawley rat embryonic (E18,
both sexes) cerebral cortical neurons were prepared as follows: the isolated
cortices free of meninges were digested with papain (0.5 mg/ml from Worthington
Biochemical Corp., Lakewood, NJ, USA) in Hibernate E without calcium (BrainBits
LLC., Springfield, IL, USA) at 37 oC for 30 min in a humidified atmosphere
containing 5% CO2. After removal of the enzymatic solution, the tissues were
gently dissociated in Neurobasal media (Invitrogen, Carlsbad, CA, USA).
Dissociated tissues were centrifuged at 300  g for 2 min. The pellet was
resuspended in Neurobasal media without antibiotics and plated on 10 cm dishes
precoated with 50 mg/ml poly-D-lysine (Sigma). Cells were plated at a density of
6  106 cells per 10 cm dish or 2.5  105 cells per well on 24-well plates (cell
viability only). Cultures were maintained in Neurobasal media supplemented with
2% B27 and 0.5 mM glutamine (all from Invitrogen) at 37 1C in a humidified
atmosphere containing 5% CO2. Half of the medium was changed every 4 days.
Culture treatments. Cortical neurons were treated for 4, 8, 16 or 24 h with
DMSO or ultra pure filtered water (controls) or with different drugs: PGJ2 and
epoxomicin in DMSO; db-cAMP, Rp-cAMPS and PACAP27 in ultra pure filtered
water added directly to DMEM without serum supplemented with 0.5 mM
glutamine and 1 mM sodium pyruvate (all from Invitrogen). The final DMSO
concentration in the medium was 0.5%. For a single administration, db-cAMP was
added to the cultures 30 min before PGJ2, whereas PACAP27 was added
in conjunction with PGJ2. For triple (3 ) administrations, each of the cAMPelevating drugs was added firstly as for the single administration, and then 4 and
8 h after that. PGJ2 was added only once at the beginning of the treatment. At the
end of the incubations, all cultures were washed twice with phosphate buffered
saline (PBS) and processed for the different assays as described below.
Cell viability assay. Cells were treated under various conditions for 4, 8, 16
or 24 h. Cell viability was assessed with the MTT assay as described in Mosmann.40
Western blotting. After treatment, cells were rinsed twice with PBS and
harvested by gently scraping into ice-cold lysis buffer (20 mM Tris-HCl, pH 7.5,
137 mM NaCl, 1 mM EGTA, 2.5 mM Na4P2O7,1 mM b-glycerophosphate, 50 mM
NaF, 1 mM phenylmethylsulfonyl fluoride, 1% NP40, 1 mM Na3VO4, 1% Glycerol
and protease inhibitor cocktail (Sigma-Aldrich)). Following lysis (at least 30 min,
 80oC), cell extracts were centrifuged (19 000  g for 10 min) at 4 oC for
separation into two fractions: NP40-soluble (supernatant) and NP40-insoluble
(pellet). The pellet was resuspended in a buffer containing 1% SDS and 10 mM
Tris-EDTA pH 7.5. Protein concentration of both fractions was determined (BCA
kit, Pierce, Rockford, IL, USA). Note that we consider SUb proteins those that are
NP40-soluble and Ub aggregates those that are NP40-insoluble as well as
detected by the filter trap assay described below. Western blot analysis was
carried out following SDS-polyacrylamide gel electrophoresis. Normalized samples
were boiled for 5 min in Laemmli buffer and loaded onto gels (40 mg of protein/
lane). Following electrophoresis, proteins were transferred onto an Immobilon-P
membrane (Millipore, Bedford, MA, USA). The membrane was probed with the

respective antibodies, and antigens were visualized by a standard chemiluminescent horseradish peroxidase method with the enhanced chemiluminescence (ECL)
reagent. Semi-quantitative analysis of protein detection was done by image
analysis with the ImageJ program (Rasband, WS, ImageJ; US NIH, Bethesda,
MD, USA; http://rsb.info.nih.gov/ij/).
Filter trap assay. After treatment, media was removed and cells were lysed
as for western blotting. Samples were normalized to 0.5 mg/ml using a buffer
containing 2% SDS and 10 mM Tris-EDTA pH 7.5. From the different extracts,
50 mg of proteins were filtered through a 0.2-mm nitrocellulose membrane
(BioRad) using a 96-well dot blot apparatus (Schleicher & Scheull Inc., Keene, NH,
USA). Each well was washed twice with washing buffer containing 0.1% SDS and
10 mM Tris-EDTA, pH 7.5. Captured aggregates were detected by immunoblotting
using the anti-ubiquitin and the TAU C3 antibodies.
In-gel proteasome activity and levels. Upon treatment with vehicle
(control, DMSO or water) or the respective drugs, cells were washed twice with
PBS and harvested for the in-gel assay as described in Wang et al.9 The native
gels loaded with 30 mg protein/lane, were run at 150 V for 120 min. The in-gel
proteasome activity was detected by incubating the native gel on a rocker for
10 min at 37 oC with 15 ml of 300 mM Suc-LLVY-AMC followed by exposure to UV
light (360 nm). Gels were photographed with a NIKON Cool Pix 8700 camera with
a 3-4219 fluorescent green filter (Peca Products, Inc., Beloit, WI, USA). Proteins
on the native gels were transferred (110 mA) for 2 h onto PVDF membranes.
Immunoblotting was carried out for detection of the 20S and 26S proteasomes
with the anti-b5 subunit antibody, which reacts with a subunit of the 20S core
particle, therefore detects 26S and 20S proteasomes. The antigen was visualized
by a chemiluminescent horseradish peroxidase method with the ECL reagent.
Intracellular cAMP. After treatment, media was removed and 500 ml of 0.1 N
HCl were added to each dish followed by incubation for 5 min. Cell lysates were
harvested and centrifuged at 600  g for 10 min at room temperature. The
supernatant was used directly in the non-acetylated version of the assay. cAMP
levels were determined with a non-radioactive assay kit following manufacturer’s
specifications. Absorbance was measured at 405 nm with correction at 570 nm,
with a PowerWave HT Spectrophotometer (Winooski, VT, USA). cAMP
concentration (pmol/mg protein) for each sample was determined according to
the kit’s instructions.
Caspase activity assays. Caspase activity assays (for caspases 3, 8 and
9) were carried out with caspase colorimetric assay kits from Biovision (Mountain
View, CA, USA) following manufacturer’s specifications.
Statistical analysis. Statistical significance was estimated using one-way
ANOVA (Tukey–Kramer multiple comparison test) with the Instat 2.0, Graphpad
Software (San Diego, CA, USA).
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